Lee Tien-Li

CEO Lee Tien-Li buys 7,000 shares at $14.48, extending strong AARD purchase pattern; stock +34.5% (30-day), +68.0% (90-day).

Lee Tien-Li acquired 7,000 shares at $14.48 on 2025-12-11, adding to a consecutive string of five prior purchases at Aardvark Therapeutics dating back to September 2025. His same-ticker history shows measurable outcomes on three of those earlier buys: 30-day returns of +91.2%, +107.9%, and +105.5%, with corresponding 90-day returns of +83.6%, +78.8%, and +73.0%. All three of these prior trades proved well-timed at the 90-day mark. The current purchase occurs as AARD trades at $14.43, within its 52-week range of $7.00–$17.41, and follows a 30-day surge of +34.5% and 90-day gain of +68.0%. While the company reports zero revenue in the latest quarter and a net loss of $-16,316,000, the repeated and consistent accumulation pattern across five calendar months paired with the measurable outperformance of three prior buys merits attention from investors evaluating management's conviction in the near-term trajectory.

CEO Lee Tien-Li bought 10,000 shares at $9.66 avg on 2025-09-15; stock down 40.5% from 52-week high, revenue zero, losses mounting.

Lee Tien-Li, CEO of Aardvark Therapeutics, purchased 10,000 shares in two separate transactions (6,500 at $9.51 and 3,500 at $9.94) on 2025-09-15 for a combined $96,623.60, bringing his holdings to 1,543,384 shares. The timing coincides with severe negative price momentum: the stock is -40.5% from its 52-week high of $17.25 and down 4.8% over 30 days and 15.1% over 90 days. Operationally, the company reported zero revenue in the latest quarter with a net loss of $14,367,000.00, a concerning profile for a biotech-stage firm. His cross-ticker track record shows 4 prior open-market buys averaging -37.4% return at 30 days and -43.2% at 90 days with a 0.00% win rate, suggesting his prior purchase timing decisions have not been favorable; at this same ticker, his February 2025 buy has already posted -43.2% 90-day returns. Investors should monitor whether this accumulation reflects access to non-public development data or simply persists the pattern of unfavorable entry points.

CEO Lee Tien-Li buys 20,000 shares in 3 tranches (20.0K shares) for $160.7K at avg $8.03, now -50.2% from 52-week high.

Lee Tien-Li, CEO of Aardvark Therapeutics, executed 3 separate purchases totaling 20,000 shares for $160,654.00 between September 10–12, 2025, at a blended average price of $8.03 per share. The stock now trades at $8.59, yet stands -50.2% from its 52-week high of $17.25 and has declined -23.3% over the past 30 days and -20.0% over 90 days. More concerning is the insider's prior purchase history at this ticker: a February 2025 buy at AARD delivered -37.4% after 30 days and -43.2% after 90 days, establishing a 0% win rate on same-ticker timing. Across all tickers, the insider's average 90-day return on prior buys is -43.2%. Against this backdrop, the company reported zero revenue in the latest quarter and a net loss of $14.4M, with a market cap of $186.4M, indicating material operational distress.

CEO Lee Tien-Li bought 16,542 shares at $16.00 on 2025-02-14; 3 other insiders also bought within 14 days

CEO Lee Tien-Li purchased 16,542 shares for $264,672.00 four trading days before the current price of $14.90, representing a 1.1% increase to his post-transaction holdings of 1,496,175 shares. The transaction occurs in the context of a cluster pattern: 3 other insiders also bought within the past 14 days. This coordinated buying activity across multiple executives at a recently listed company (4 trading days post-IPO) warrants investor attention, though the stock has since traded below the CEO's entry price. Note that the Form 4 filing indicates a derivative-conversion transaction; the CEO's full position includes both Table I shares and derivative securities not yet populated in our database, so the reported 1,496,175 shares do not necessarily represent his total economic exposure.